Objective: To describe the latest demographic and clinical profiles of patients with advanced Parkinson’s disease (aPD) enrolled in the ELEGANCE study who have received treatment for up to two years.

Background: Understanding the clinical characteristics of LECIG treated aPD patients in routine clinical practice allows better interpretation of its real-world effectiveness, safety profile and patient‑reported outcomes. Prior interim data characterised an initial cohort of aPD patients treated with LECIG (n=167)¹; continued enrolment and follow‑up warrant an updated description of the demographics of this larger population.

Method: ELEGANCE is an international, non-interventional study of aPD patients treated with LECIG in routine care. This interim analysis includes all patients enrolled up to February 2026. including those who have completed Visit (V) 5 (up to two years of treatment). Descriptive statistics were generated for age, sex, ethnicity, disease duration, Hoehn and Yahr (H&Y) stage, prior device‑aided therapies and reason for switching to LECIG.

Results: A total of 312 patients were included in this analysis; mean age: 68.3 years, 41.0% female; predominantly Caucasian (95%). Among 310 with available data, mean PD duration was 12.85 years, and mean H&Y stage was 3.21, consistent with aPD. 51 (16.5%) switched to LECIG from another infusion system (apomorphine infusion [n=14], levodopa–carbidopa intestinal gel [LCIG] infusion [n=35]), while the rest switched from oral therapy. Reasons for switching from subcutaneous/duodenal infusion were insufficient efficacy of previous therapy (n=29), poor compliance (n=1) and ‘other’ reasons (n=21), including smaller or lighter pump preference, previous infusion therapy adverse effects (e.g. impulse control disorder or cutaneous nodules), or desire for 24‑hour therapy.

Conclusion: This updated analysis shows that patients receiving LECIG in the ELEGANCE study are typically in their late sixties, with long‑standing aPD and have limited prior exposure to device‑aided infusion therapies. As a subgroup that switched from other infusion devices for a variety of reasons, this provides important context for interpreting the outcomes observed in the ELEGANCE study.

References: 1. Weiss D, et al. Mov Disord Clin Pract, 12: 1075-1085.

« Back to 2026 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/demographic-and-clinical-characteristics-of-advanced-parkinsons-disease-patients-receiving-levodopa-entacapone-carbidopa-intestinal-gel-lecig-in-the-elegance-study-an-updat/